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Abstract
Background: Epidemiological studies have shown an association between the ACE gene I/D polymorphism with 
arterial hypertension, specifically the DD genotype, in different populations. The objective of this study is to evaluate 
the association between ACE polymorphisms (Insertion, Deletion or I/D) and essential hypertension in a popula-
tion of Lima, Peru.
Material and methods: This is a study of cases (essential arterial hypertension) and controls, with determination of 
the ACE I/D genotype.
Results: Cases (65) and controls (39) had a mean age (standard deviation) of 74.3 (7.9) and 72.6 (6.5) (p = 0.24). 
In cases, the genotype frequencies DD, ID, and II were 6 (9.2%), 28 (43.1%) and 31 (47.7%), respectively. In con-
trols, the genotype frequencies DD, ID, and II were 6 (15.4%), 14 (35.9%) and 19 (48.7%). The Hardy-Weinberg 
equilibrium analysis in cases and controls was p = 0.93 and p = 0.23, respectively. No significant associations be-
tween genotype DD vs. ID + II (OR = 0.56, 95% CI: 0.17–1.87, p = 0.34) or II vs. DD + ID (OR = 0.95, 95% CI: 
0.43–2.12, p = 0.92) and essential hypertension were found.
Conclusions: The ACE I/D polymorphism was not associated with hypertension in our sample.
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Introduction
Hypertension is one of the most common non-com-
municable diseases in the world, with a prevalence of 
22% [1] and in Peru 23.7% [2]. Essential hyperten-
sion refers to primary hypertension where an aetiol-
ogy has not been clearly identified. Arterial hyper-
tension has been associated with various risk factors 
including age, sex, demographic, lifestyle, environ-
mental and genetic. The heritability of hypertension 
ranges from 48 to 60% for systolic hypertension and 
34 to 67% for systo-diastolic [3], although it should 
be noted that heritability does not identify which ge-
netic difference is more significant or the mechanism 
by which it exerts its effect on blood pressure [3].
Currently, 2129 genes associated with hyperten-
sion have been reported, among which is the an-
giotensin-converting enzyme (ACE) gene [4]. The 
ACE enzyme converts inactive angiotensin I into 
active angiotensin II and also degrades bradykinin 
to maintain homeostasis of blood pressure. ACE 
is a membrane-bound dipepetidyl carboxypeptidase 
ectoenzyme, located in the endothelium of blood 
vessels and is the main component of the renin-
angiotensin and kallikrein–kinin system. The ACE 
gene is encoded on the long arm of chromosome 
17 (17q23), consists of 26 exons and 25 introns. 
The presence or absence of a 287bp element in the 
ACE gene gives rise to three genotypes: insertion 
(II), insertion/deletion (I/D) and deletion (DD). 
Epidemiological studies have shown an association 
between the ACE gene I/D polymorphism with ar-
terial hypertension, specifically the DD genotype 
in different populations [5]. On the other hand, 
certain differences in response have been evidenced 
in the antihypertensive inhibitors of the angiotensin 
converting enzyme (ACEI) or angiotensin II receptor 
blockers (ARBs), according to ACE polymorphism 
and the study population [5].
The present study aims to evaluate the association 
between ECA polymorphisms (Insertion/Deletion 
or I/D) and hypertension essentially in a population 
of Lima, Peru.
Material and methods
An observational, retrospective case-control study 
was carried out. 104 patients (65 cases and 39 con-
trols) equal to or older than 60 years were included. 
Patients with a diagnosis of essential hypertension 
verified in clinical history and receiving treatment 
with antihypertensives for more than 3 months were 
called cases; and controls were those with a clinical 
history and evaluation without criteria of arterial 
hypertension or taking antihypertensives. The study 
was conducted at the Hospital de Geriátrico of the 
Almenara Hospital in Lima, Peru, between January 
2016 and December 2018. The 104 people of mes-
tizo ancestry, from Lima, who entered the study, were 
part of an investigation on the use of angiotensin II 
antagonists, memory performance and its relation-
ship with ACE polymorphisms. The research proj-
ect was approved by the Almenara Hospital Ethics 
Committee, and all participants signed an informed 
consent. The method of patient selection was not 
probabilistic. 
Genomic analysis
After signing the informed consent, whole blood 
samples were collected in EDTA tubes of each pa-
tient. The DNA was extracted from the leukocytes 
using the standard phenol/chloroform method and 
amplified by PCR (polymerase chain reaction). ACE 
I/D polymorphism (rs1799752) was detected using 
the method described by Franken et al [6].
Statistical analysis
Descriptive statistical data were presented as a per-
centage (%), mean with standard deviation (SD) 
and range. The Chi-square analysis was used for the 
Hardy-Weinberg equilibrium deviation evaluation. 
The genotype distribution and allele frequencies of 
each polymorphism were compared between cases 
and control subjects by the c2 test. In establishing 
the association between hypertension and ACE I/D 
genotypes, the odds ratio (OR) and 95% confidence 
intervals (CI) were used. It was considered statisti-
cally significant if p < 0.05. The SPSS statistical pack-
age was used to analyse the data.
Results
The population studied consisted of 46 men (44.2%) 
and 58 women (55.8%), with a mean age and stan-
dard deviation (SD) of 73.7 (7.4) years, range be-
tween 60–90 years. In the population studied the fre-
quency of D/D, I/D and I/I genotypes was 12.65%, 
43.66% and 43.66 respectively, with allelic D and 
I frequency of 34.5% and 65.5% respectively. The 
analysis of the distribution of genotype frequen-
cies showed that it was consistent with a popula-
tion in Hardy-Weinberg equilibrium (c2 = 0.1051; 
p = 0.746) (Tab. 1).
The mean and standard deviation (SD) of age of 
the cases and controls were 74.34 (7.87) and 72.56 
(6.60 years) (p = 0.24). The cases were male 32 
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(49%) and female 33 (51%), while controls were 
male 14 (36%) and female 25 (64%). In the cases the 
genotype frequency DD, ID, and II were 6 (9.23%), 
28 (43.08%), 31 (47.69%) respectively. In the con-
trols the genotype frequency DD, ID, and II were 6 
(15.38%), 14 (35.90%), 19 (48.72%). The Hardy- 
-Weinberg equilibrium analysis in cases and controls 
was p = 0.93 and p = 0.23 respectively. No significant 
association of genotype DD vs. ID + II (OR = 0.56, 
95% CI: 0.17–1.87, p = 0.34) or II vs. DD + ID 
(OR = 0.95, 95% CI: 0.43–2.12, p = 0.92) with es-
sential hypertension was found (Tab. 2).
Discussion
The present study did not find an association be-
tween ACE polymorphisms and essential hyperten-
sion in a population of Lima, Peru.
The results of studies on the relationship between 
ECA polymorphisms and essential hypertension dif-
fer significantly depending on the geographic loca-
tion and population studied. The main study with 
positive results is the meta-analysis conducted by 
Mengesha et al. in the African continent, which 
included 6 studies, finding that patients with the D 
allele were 1.49 times more likely to develop essential 
hypertension compared to the carriers of the I allele 
(OR: 1.49; CI: 1.07–2.07), additionally found that 
those from sub-Saharan Africa were more susceptible 
than those from North Africa [5]. A study conducted 
in the USA with Mexican-Americans found an as-
sociation between the D allele and essential arterial 
hypertension [7]. Studies in India have also reported 
an association between the ACE/(D/D) genotype 
and essential hypertension [8–11]. 
On the other hand, the negative results are re-
ported by Agerholm et al. [12], the meta-analytical 






Age (± SD) 72.56 (6.60) 74.34 (7.87) 0.24
Sex
Male (%) 14 (35.90%) 32 (49.23%) 0.19
Female (%) 25 (64.10%) 33 (50.77%) 0.19
Body mass index 27.28 (4.21) 28.02 (3.89) 0.37
Smoking 3 (7.69%) 2 (3.13%) 0.30
Dyslipidaemia 9 (23.08%) 27 (41.54%) 0.07
Diabetes mellitus type 2 7 (17.95%) 14 (21.54%) 0.66
Genotype
D/D n (%) 6 (15.38%) 6 (9.23%) 0.42
I/D n (%) 14 (35.90%), 28 (43.08%) 0.47
I/I n (%) 19 (48.72%). 31 (47.69%) 0.92
SD — standard deviation
Table 2. Relationship between angiotensin convertase enzyme (ACE) polymorphisms and essential hypertension in a population of Lima, Peru
Genotype ACE Controls (n = 39) Cases (n = 65) OR 95% CI p value
DD vs. ID + II
n (%) 6 (15.38) 6 (9.23%) 0.56 0.17–1.87 0.34
ID vs. II + DD
n (%) 14 (35.9%) 28 (43.08) 1.35 0.60–3.06 0.47
II vs. DD + ID
n (%) 19 (48.72) 31 (47.9%) 0.95 0.43–2.12 0.92
D vs. I
n (%) 26 (33) 40 (31%) 0.89 0.49–1.62 0.70
The Hardy-Weinberg equilibrium 
(p value) 0.23 0.93      
OR — odds ratio; CI — confidence interval
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study included 45 studies in white people in Europe 
and the US, finding no relationship between the 
ACE gene and essential hypertension. In addition, 
two studies have been published with the same nega-
tive results between Hawaiian Americans and African 
Americans [13, 14].
In Latin America, a study in Colombia (Bucara-
manga) found that DD genotype was 1.56 times 
more frequent in hypertensive patients, compared to 
allele I [15]. Bonfim-Silva et al. [16] in their study 
with Afro-Brazilian and Caucasian population found 
no association; neither did the study conducted in 
Cuba in a multi-ethnic sample [17]. A recent study 
in Brazil also found no relationship; however, this 
relationship became significant only when ACE and 
ACE2 polymorphisms were combined [18]. Prior to 
this study, the only study conducted in Peru (Lima 
and Chincha), was that of Lizaraso et al. and found 
no relationship between these polymorphisms and 
essential hypertension [9].
The importance of knowing the association of 
ACE gene and essential hypertension is to know if 
there is a genetic basis in the effectiveness of antihy-
pertensive pharmacotherapy with angiotensin con-
verting enzyme inhibitors (ACEIs) or angiotensin 
II receptor blockers (ARBs). It has been described 
that the effectiveness of ACEIs is diminished in 
the African and African-American population and 
these antihypertensives are not of first choice in that 
population [20, 21]. Coincidentally the ACE D/D 
genotype is related to essential hypertension in this 
population [5]. It has been described that the rate of 
early responses to ramipril is more frequent in pa-
tients with genotypes ID and II, compared to DD, in 
patients from India; once again it is compatible with 
the finding of the association of DD with HT in that 
country [22]. Another study in Malaysia, found that 
DD carriers respond better to enalapril or lisinopril 
than ID and II [23]. On the other hand, genotypes 
II respond better than DD or ID to ARB such as 
ibersartan [24]. One of the practical objectives of 
this type of pharmacogenetic studies is to convert the 
ACE polymorphism determination into a marker of 
individualized antihypertensive response to ACEIs 
and ARBs.
The present study has some limitations. The main 
one is the number of patients is relatively small. 
However, it provided genetic data that can be used 
to initiate other studies designed to know the phar-
macogenetics of ACEIs and ARBs in the Peruvian 
population, having ACE genotypes as markers.
In conclusion, the present study did not find an 
association between ACE polymorphisms (Insertion/
Deletion or I/D) and essential hypertension in the 
study population. More research is required in dif-
ferent populations of the country, adding other can-
didate genes.
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